Passage Bio, Inc. Stock Price, News & Analysis

Passage Bio (NASDAQ: PASG) will host a conference call on November 10, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and recent business updates. The company focuses on genetic therapies for CNS disorders and is advancing three clinical programs targeting GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Passage Bio collaborates with the University of Pennsylvania’s Gene Therapy Program for its research and development efforts. Archived webcasts will be available post-event for 30 days.

Passage Bio (Nasdaq: PASG) announced the appointment of Dr. William Chou as its new CEO, granting him inducement stock options for 665,500 shares at an exercise price of $1.32 per share. These options will vest over four years, with 25% vesting after the first year and the remainder in monthly installments. The company focuses on developing gene therapies for central nervous system disorders, including GM1 gangliosidosis and Krabbe disease, and has established a collaboration with the University of Pennsylvania's Gene Therapy Program.

Passage Bio (Nasdaq: PASG) has appointed Dr. William Chou as CEO, effective immediately. Dr. Chou, an experienced executive with a background in gene therapies, succeeds interim CEO Edgar Cale, who will remain as general counsel. The leadership change aims to enhance the company’s focus on developing transformative therapies for central nervous system disorders. Dr. Chou is expected to leverage his expertise to advance ongoing clinical programs and establish the company as a leader in genetic medicine.

Passage Bio (NASDAQ: PASG) announced that CFO Simona King will present at the Chardan Genetic Medicines Conference from October 3-4, 2022, in New York City. The presentation will be a fireside chat on October 3 at 1:00 p.m. ET, and it will be accessible via live webcast on their Investors & Media page. Passage Bio focuses on developing therapies for central nervous system disorders and is advancing multiple clinical programs aimed at conditions like GM1 gangliosidosis and Krabbe disease. More details can be found on their official website.

Passage Bio (Nasdaq: PASG) announced the grant of 54,000 stock options to new employees as part of their employment inducements. The options have an exercise price of $2.20 per share, matching the stock's closing price on August 15, 2022. Vesting occurs over four years, with 25% vesting after one year and the remainder in monthly installments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Passage Bio's commitment to attracting talent in the competitive biotech sector.

Passage Bio (Nasdaq: PASG) announced the dosing of the first patient in its Phase 1/2 upliFT-D clinical trial for PBFT02, a gene therapy for frontotemporal dementia (FTD) with granulin mutations. This milestone is significant for advancing PBFT02, which aims to address the unmet need for effective treatments in FTD with no approved disease-modifying therapies. The trial evaluates the safety and tolerability of a single AAV-delivered dose of PBFT02. The U.S. FDA has granted Fast Track and Orphan Drug designations for this innovative therapy.

Passage Bio, a clinical-stage genetic medicines company, will have CFO Simona King participate in a virtual panel at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:35 a.m. ET. The panel discussion, titled "Headspace - Updates in CNS Gene Therapy," will focus on advances in gene therapy for central nervous system disorders. A live webcast will be available on their website and a replay will be accessible for 30 days post-event. Passage Bio is dedicated to developing therapies for CNS diseases with limited treatment options, and is advancing three clinical programs in notable disorders.

Passage Bio (NASDAQ: PASG) has advanced its Imagine-1 clinical trial for GM1 gangliosidosis, now in the final cohort, following Independent Data Monitoring Committee recommendations. The company presented promising long-term clinical data at ASGCT and received IND clearance for PBML04 for metachromatic leukodystrophy. As of June 30, 2022, cash reserves were $239.3 million, sufficient to fund operations into Q2 2024. The company reported a net loss of $39.5 million for Q2 2022, an improvement from $48.4 million the previous year.

Passage Bio (NASDAQ: PASG) will host a conference call on August 4, 2022, at 8:30 a.m. ET to discuss its Q2 2022 financial results and business updates. The call aims to provide insights into the company's advancements in developing gene therapies for central nervous system (CNS) disorders, including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Passage Bio has established collaborations with the University of Pennsylvania's Gene Therapy Program to enhance its clinical pipeline. An archived webcast will be available following the event.